CME/CE podcast

—

Host: Aditya Bardia, MD, MPH The recent approvals of therapies for hormone-receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) have augmented the treatment armamentarium in this setting, giving clinicians more options for their patients. However, it may be challenging to select the optimal therapy for individual patients. Moreover, it is important to differentiate between the 2 available TROP2-directed antibody-drug conjugates (ADCs). This activity reviews challenges in treating HR+, HER2- MBC, the role of TROP2-directed ADCS, and how to tailor therapy for individual patients.…

1
Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma

8 weeks ago

—

Host: Tycel Phillips, MD Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.…

1
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

21 weeks ago

—

Host: Jorge E. Cortes, MD Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that can maintain response rates. This activity reviews the current treatment options for newly diagnosed disease and the importance of integrating patient preference when planning therapeutic regimens.…

1
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

24 weeks ago

—

Host: Mark Socinski, MD This animated podcast explores the evolving role of ALK inhibitors in managing early-stage non-small cell lung cancer (NSCLC). Dr. Mark Socinski discusses molecular profiling as a cornerstone for identifying ALK fusion–positive cases and highlights clinical data from pivotal trials. He also addresses the challenges of treatment adherence, toxicity management, and the importance of surrogate endpoints in early-stage disease. The discussion concludes with key takeaways on integrating targeted therapies into standard care for early-stage resectable NSCLC.…

1
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

36 weeks ago

—

Host: Sara M. Tolaney, MD, MPH This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care. FDA Approval January 2025: On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients with HR+, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who have progressed on one or more endocrine therapies in the metastatic setting. On January 17, 2025, datopotamab deruxtecan (Dato-DXd) was approved by the FDA for patients with HR+/HER2- unresectable or metastatic breast cancer who have received prior endocrine therapy and chemotherapy for unresectable or metastatic disease.…

1
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting

38 weeks ago

—

Host: Helena Yu, MD The treatment of EGFR- mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR- mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity.…

1
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL

46 weeks ago

—

Host: Matthew S. Davids, MD, MMSc Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL. In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can ……

1
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

46 weeks ago